This is a single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome.
Phase II single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome.
Objectives
Primary
- Evaluate overall response rate (ORR) to CHOP-O according to the Revised Response Criteria for Malignant Lymphoma (Cheson criteria).
Secondary
- Feasability of recruitment.
- Progression free survival (PFS).
- Overall Survival (OS).
- The clinical benefit and changes in patient reported outcome measures (PRO).
- Safety and tolerability.
Trial Publications
The primary results publication can be found here.
The study protocol publication can be found here.